Completed PHASE3 INTERVENTIONAL 2-arm NCT01216111

Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)

A Prospective， Randomized， Open-label， Multicentric，phaseIII Clinical Trial Compared With PC and CEF100 Followed by Docetaxel as Adjuvant Chemotherapy Regimen for Chinese Primary Triple Negative Breast Cancer Patients

Sponsor: Chinese Anti-Cancer Association

Conditions Triple Negative Breast Cancer

Interventions Paclitaxel Cisplatin fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)

Updated 7 times since 2017 Last updated: May 17, 2020 Started: Jan 1, 2011 Primary completion: Apr 20, 2016 Completion: Apr 20, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Triple Negative Breast Cancer, this trial is completed. The trial is conducted by Chinese Anti-Cancer Association and has accumulated 7 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Available → Completed · Phase: None → PHASE3
Apr 2018 — Jun 2020 [monthly]

Available

Phase: NA → None

▶ Show 2 earlier versions

Feb 2017 — Apr 2018 [monthly]

Available NA

Status: Unknown Status → Available
Jan 2017 — Feb 2017 [monthly]

Unknown Status NA

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Anti-Cancer Association
Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.